Rectal Cancer
Conditions
Interventions
The control group:5-Fu based Radiotherapy
The experimental group:XELOX induction chemotherapy and 5-Fu based radiotherapy
Sponsors
Shanghai ChangZheng Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. histopathologically confirmed rectal adenocarcinoma; 2. locally advanced rectal cancer (LARC,T3-T4 and/or N+) assessed by both plevic magnetic resonance imaging (MRI) and endorectal ultrasonography (EUS); 3. the inferior margin within 12 cm from the anal verge; 4. aged from 18 to 75 years; 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; 6. good blood, heart, liver and renal functions.
Exclusion criteria
Exclusion criteria: 1. distant metastasesincluding but not limited to the liver, lungs and brain; 2. with other malignant tumor; 3. previous treatment including chemotherapy or radiotherapy for LARC; 4. patients had received major surgery procedure with four weeks; 5. patients with uncontrolled high-risk hypertension or arrhythmias; 6. current or recent take anticoagulants or thrombolytic agents; 7. the patients who can not cooperate with the examination and treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor response;Toxicity; | — |
Secondary
| Measure | Time frame |
|---|---|
| The time of surgery;Amount of bleeding during operation;Postoperative complication; | — |
Countries
China
Contacts
Public ContactZhiqian Hu
Outcome results
None listed